Product
Supplier
Encyclopedia
Inquiry
Home > News > Pharma News > Trump Nominates Anti-Vaccine Expert Kennedy to Lead HHS

Trump Nominates Anti-Vaccine Expert Kennedy to Lead HHS

ECHEMI 2024-11-18

On November 14, 2024, President Donald Trump officially announced his intention to nominate Robert F. Kennedy Jr. to serve as Secretary of the Department of Health and Human Services (HHS) in his new administration. This decision has aroused widespread public concern and controversy.


Since 2005, Kennedy has continued to argue for a link between vaccines and autism, although this view has been widely rejected by the scientific community. He has also argued that the COVID-19 virus is "racially directed," primarily affecting whites and blacks, while Ashkenazi Jews and Chinese are less affected.


In announcing his nomination, Trump emphasized Kennedy's commitment to reforming the U.S. health care system to ensure the public is protected from harmful chemicals, pollutants, pesticides, drugs and food additives. He also said Kennedy would work to restore HHS's tradition of scientific research and increase transparency to address the nation's chronic disease epidemic.


If Trump's nomination is confirmed by the Senate, Kennedy would be responsible for leading HHS, which has a budget of $1.7 trillion, and overseeing key agencies including the Food and Drug Administration (FDA), the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the Centers for Medicare and Medicaid Services (CMS). Kennedy had previously revealed plans to lay off 600 NIH employees on his first day in office, signaling a potential major change for the agency.


The nomination has been widely discussed in medical and political circles. Many public health experts have expressed concern about Kennedy's anti-vaccine stance, arguing that it could have implications for current vaccination policies and public health strategies in the United States. At the same time, some members of the Republican Party are also wary of the nomination, fearing that it may cause unnecessary controversy.


The Senate has yet to vote on the nomination, and it remains to be seen whether Kennedy will succeed.

Disclaimer: ECHEMI reserves the right of final explanation and revision for all the information.

Looking for chemical products? Let suppliers reach out to you!

Comment
Comment
  • Life Sciences Industry Overview

    The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.
    Published in: June.2026

Trade Alert

Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)

Scan the QR Code to Share

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.